| Claire Williams, MD | |
|
186 Providence St, West Warwick, RI 02893-2508 | |
| (401) 615-2800 | |
| (401) 615-2805 |
| Full Name | Claire Williams |
|---|---|
| Gender | Female |
| Speciality | Pediatric Medicine |
| Experience | 9 Years |
| Location | 186 Providence St, West Warwick, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144608795 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Thundermist Health Center | 1557270477 | 131 |
News Archive
Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.
This study, published in the journal Cells, is based on others (all of which employed experimental models) previously conducted by researchers at the Biomedical Research Centre of the University of Granada, the ‘López-Neyra' Institute of Parasitology and Biomedicine, and the ‘Virgen de las Nieves' University Hospital in Granada
AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.
SRI/Surgical Express, Inc., a leading provider of reusable surgical device reprocessing services supporting the healthcare industry, today announced financial results for its fourth quarter and year ended December 31, 2009.
LifeSignals announced today that it received FDA clearance for its wireless LP1100 Life Signal Patch for enabling the next generation of wearable, healthcare monitoring devices.
› Verified 8 days ago
| Entity Name | Thundermist Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700041001 PECOS PAC ID: 1557270477 Enrollment ID: O20040211000909 |
News Archive
Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.
This study, published in the journal Cells, is based on others (all of which employed experimental models) previously conducted by researchers at the Biomedical Research Centre of the University of Granada, the ‘López-Neyra' Institute of Parasitology and Biomedicine, and the ‘Virgen de las Nieves' University Hospital in Granada
AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.
SRI/Surgical Express, Inc., a leading provider of reusable surgical device reprocessing services supporting the healthcare industry, today announced financial results for its fourth quarter and year ended December 31, 2009.
LifeSignals announced today that it received FDA clearance for its wireless LP1100 Life Signal Patch for enabling the next generation of wearable, healthcare monitoring devices.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Claire Williams, MD 186 Providence St, West Warwick, RI 02893-2508 Ph: (401) 615-2800 | Claire Williams, MD 186 Providence St, West Warwick, RI 02893-2508 Ph: (401) 615-2800 |
News Archive
Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.
This study, published in the journal Cells, is based on others (all of which employed experimental models) previously conducted by researchers at the Biomedical Research Centre of the University of Granada, the ‘López-Neyra' Institute of Parasitology and Biomedicine, and the ‘Virgen de las Nieves' University Hospital in Granada
AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.
SRI/Surgical Express, Inc., a leading provider of reusable surgical device reprocessing services supporting the healthcare industry, today announced financial results for its fourth quarter and year ended December 31, 2009.
LifeSignals announced today that it received FDA clearance for its wireless LP1100 Life Signal Patch for enabling the next generation of wearable, healthcare monitoring devices.
› Verified 8 days ago